XTalks

DECEMBER 1, 2021

While researchers are still working out the epidemiological, clinical and molecular details of Omicron, so far, it is known that the variant is laden with up to 50 mutations, 30 or so of which are just in its outer spike (S) protein. The company said as a result, Omicron’s spike mutations do not impact the accuracy of its tests.

Gene 105

Gene Genome Genomics Genetics 105

XTalks

MAY 1, 2023

This makes Qalsody the first approved treatment to target a genetic cause of ALS. Since SOD1 mutations were first identified as a cause of ALS 30 years ago, the familial ALS community has been searching for genetically targeted treatments. To date, over 200 mutations in the SOD1 gene have been associated with the development of ALS.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

XTalks

JUNE 16, 2021

The company’s candidate recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, is being evaluated in the PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19) Phase III trial, which has close to 30,000 participants across 119 states in the US and Mexico.

Vaccination 98

Vaccination Vaccine Protein Trials 98

XTalks

AUGUST 6, 2020

Epidiolex is the only FDA-approved formulation that contains CBD derived from the cannabis plant. CBD is the most abundant non-psychoactive cannabinoid compound found in the cannabis plant, making up about 40 percent of the plant’s extract, which contains over 100 different cannabinoid compounds.

FDA Approval 64

FDA Approval Protein Containment Genetic Disease 64

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

XTalks

AUGUST 17, 2020

protein-based biologics) and vaccine treatments. protein-based biologics) : are those which bind to specific components (i.e. A growing area in the immunotherapy space is the development of biological modulators, which are genetically engineered proteins that target specific components of the immune system.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

OCTOBER 26, 2020

The agreement covers the gene therapy program targeting OTOF (OTOF-GT), the gene encoding the otoferlin protein. Sensorion is currently advancing two preclinical gene therapy programs conducted under a broad multi-program research partnership with the Genetics and Physiology of Hearing Unit at Institut Pasteur (Paris). About Novasep.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

XTalks

NOVEMBER 23, 2020

Developed by researchers at the University of Oxford, the COVID vaccine is an adenovirus vector-based vaccine derived from chimpanzees that contains a genetically engineered virus that causes the common cold in chimpanzees, along with the spike protein of the SARS-CoV-2 coronavirus.

Vaccination 97

Vaccination Vaccine Clinical Trials Clinical Trials 97

XTalks

MARCH 10, 2023

It is caused by a mutation in the FXN gene , which is responsible for the production of the protein frataxin. Usually diagnosed during adolescence ( 10-15 years ), Friedreich’s ataxia shortens life expectancy, causing the patient to be wheelchair bound within the first 10 to 20 years of diagnosis and most often leading to death.

FDA Approval 52

FDA Approval Engineer Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 8, 2020

The genetic material contains SARS-CoV-2 spike protein. The vaccine uses a replication-deficient chimpanzee viral vector based on a weakened version of a common cold virus that causes infections in chimpanzees. The Phase 3 trial is being implemented as part of Operation Warp Speed.

Manufacturing 83

Manufacturing Vaccination Vaccine Allergies 83

XTalks

SEPTEMBER 15, 2020

A vaccine developed by Swedish company Diamyd Medical has demonstrated significant treatment efficacy in a predefined genetic subgroup of individuals with type 1 diabetes in a Phase IIb clinical trial. Specifically, the vaccine contains human recombinant glutamate decarboxylase 65 (GAD65) protein conjugated to aluminum hydroxide (GAD-alum).

Vaccination 103

Vaccination Vaccine Insulin Trials 103

XTalks

NOVEMBER 10, 2023

The US Food and Drug Administration (FDA) has approved Takeda Pharmaceuticals’ Adzynma, the first recombinant protein product for prophylactic (preventive) or on‑demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), an ultra-rare blood clotting disorder.

FDA Approval 59

FDA Approval Gene Therapy Gene Clinical Trials 59

XTalks

FEBRUARY 11, 2021

This has ushered in a new era of genomics that is fostering rapid, detailed and personalized insights into human genetics. Xtalks is celebrating the International Day of Women and Girls in Science with a special overview of notable female scientists who have made revolutionary contributions to the field of genetics.

Genetics 119

Genetics DNA Genome Genomics 119

Drug Discovery World

MARCH 7, 2023

DDW Editor Reece Armstrong takes a look at Qatar’s drug discovery and life sciences market, exploring how the country is utilising innovative technologies in its approach to healthcare. More research work focuses on dissecting the genetic architecture of other diseases such atrial fibrillation and arrhythmia,” Dr Saad says.

Biobanking 52

Biobanking Drugs Genome Genomics 52

XTalks

DECEMBER 13, 2023

3) Fulgent Genetics Compound annual growth rate: 260 percent Fulgent Genetics, headquartered in California, is a technology-driven company with a strong presence in clinical diagnostics and therapeutic development. Alpine Immune Sciences has recently announced an augmentation in its R&D investment. million and $38.8

Genetics 111

Genetics Vaccination Vaccine DNA 111

pharmaphorum

SEPTEMBER 18, 2020

The same year, AZ also entered into its third collaboration agreement with Astex Therapeutics, this time to develop small-molecule protein kinase B (PKB) to further contribute in the fight against cancer. AstraZeneca’s first acquisition following its creation was of KuDOS Pharmaceuticals, a UK biotech company, for £120 million in 2005.

Pharma Companies 116

Pharma Companies Sales Vaccination Vaccine 116

XTalks

JANUARY 14, 2021

Hahn, MD said, “The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients.”. The FDA says that while they may be impacted by new genetic variants of SARS-CoV-2, “the impact does not appear to be significant.”. As scientists learn more about the new B.1.1.7

Genetics 98

Genetics Genome Genomics Protein 98

XTalks

NOVEMBER 7, 2022

Dr. Bahassi explained that technological advances in genetic sequencing of cfDNA have enabled liquid biopsies and led to marked increase in the detection of therapeutically-targetable mutations. Exosomes are extracellular vesicles that contain molecular cargoes (such as various proteins, RNAs and DNAs) specific to the origin cell.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

AUGUST 10, 2022

To overcome this evasion tactic, the CAR protein was developed to recognise other markers on cancer cells. CAR is a fusion protein composed of an extracellular antibody fragment that recognises antigens and an intracellular domain that directs the T cell to the tumour. Identifying the right CAR T cell target.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

XTalks

MAY 15, 2023

Fabry disease, also known as Anderson-Fabry disease, is a rare genetic disorder that falls under the category of lysosomal storage diseases. Protalix BioTherapeutics focuses on the production, development and commercialization of recombinant therapeutic proteins. The administration of Elfabrio is performed by a healthcare professional.

FDA Approval 98

FDA Approval Gene Genetics Clinical Trials 98

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells through epigenetic editing without altering the genetic sequence itself. Epigenetic Editing with CRISPR. pyogenes dCas9.

DNA 98

DNA Gene Gene Silencing Genome 98

XTalks

OCTOBER 26, 2023

The Flu versus COVID-19: Virology and Vaccines SARS-CoV-2 versus Influenza Virology Viruses contain genetic material that can either be RNA or DNA. Both influenza and SARS-CoV-2 have RNA as their genetic material. An RNA genome enables the genetic material to mutate more rapidly. remains the dominant variant.

Vaccination 105

Vaccination Vaccine RNA Manufacturing 105

XTalks

MAY 4, 2021

Researchers at the University of California San Francisco (UCSF) and the Whitehead Institute have developed a novel CRISPR-based tool called “CRISPRoff” that can switch off genes in human cells without editing the genetic sequence itself. Related: 2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences.

DNA 52

DNA Gene Gene Silencing Genome 52

Drug Discovery World

JULY 15, 2022

Nanopore sequencing relies on determination of the chemical composition of the nucleic acids by passing a single strand of nucleic acids through a protein nanopore 6. iv) Highly repetitive regions contain some of the highest mutation rates. Telomeres play an important role in normal genome function and development of human disease.

Genome 52

Genome Genomics DNA Containment 52

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Continuing trends suggest the worst may be over provided the outbreak is contained over the next few months.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92